FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973106424> ?p ?o ?g. }

• W1973106424 endingPage "1666" @default.
• W1973106424 startingPage "1666" @default.
• W1973106424 abstract "The usefulness of corticosteroids in stable COPD has been an issue of controversy for many years. Although several studies have shown benefits of these agents over placebo, it is generally recognized that this is the result of large responses to corticosteroids in a minority of patients. Several authors have attempted to determine patient characteristics which might predict responses to corticosteroids. The recent report by Weiner and colleagues (CHEST 1995; 108:1568–71) sheds an interesting light on this issue. Their study concluded that the majority of patients with COPD who respond to inhaled ß2-agonist also have a response to inhaled corticosteroids. Although the authors quote one study that supports the use of inhaled β2-agonist to identify steroid responders, several other studies have shown failure of β2-agonist reversibility to predict steroid response. Roberston and colleagues1Robertson AS Gove RI Wieland GA et al.A bouble-blind comparison of oral prednisolone 40 mg/d with inhaled beclomethasone dipropionate 1500 μg/d in patients with adult onset chronic obstructive airways disease.Eur J Respir Dis. 1986; 146: 565-569Google Scholar failed to show significant differences in reversibility to salbutalmol in 25 corticosteroid responders as compared with nonresponders. Similarly, Harding and Freedman2Harding SM Freedman S. A comparison of oral and inhaled steroids in patients with chronic airways obstruction: features determining response.Thorax. 1978; 33: 214-218Crossref PubMed Scopus (53) Google Scholar found that greater reversibility to isoprenaline during the placebo phase of their study did not predict corticosteroid response. Weir and colleagues3Weir DC Gove RI Robertson AS et al.Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate.Thorax. 1990; 45: 112-117Crossref PubMed Scopus (91) Google Scholar examined responses to corticosteroids in patients with considerable reversibility to salbutamol (>50%) and concluded that the proportion of steroid responders in that group was not different than the proportion of responders with less p2-agonist reversibility. Likewise, Eliasson et al4Eliasson O Hoffman J Trueb D et al.Corticosteroids in COPD: a clinical trial and reassessment of the literature.Chest. 1986; 89: 484-490Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar confirm a lack of relationship between β2-agonist reversibility and response to oral corticosteroid. Finally, although Mendella et al5Mendella LA Manfreda J Warren PW et al.Steroid response in stable chronic obstructive pulmonary disease.Ann Intern Med. 1982; 96: 17-21Crossref PubMed Scopus (108) Google Scholar demonstrated that significantly more steroid responders had p2-agonist reversibility, there was substantial overlap with steroid nonresponders. These results indicate that β2-agonist response cannot reliably identify steroid responders. The reasons for the impressive association between reversibility to β2-agonist and response to corticosteroids found by Weiner and colleagues are unclear. The degree of β2-agonist reversibility in this study was quite high, suggesting that patients in this study represent a small subgroup of patients with COPD. The author of the corresponding editorial (CHEST 1995; 108:1486–87) states that using β2-agonist reversibility “better identifies patients who will benefit from inhaled corticosteroids from those with … response to oral corticosteroid therapy trial.” Until more convincing data on a larger number of patients are available, corticosteroid trials remain to be the only reliable way of deciding which patients with stable COPD will benefit from inhaled corticosteroids. Inhaled Budesonide Therapy for Patients With Stable COPDCHESTVol. 108Issue 6PreviewA significant minority of patients with COPD have favorable response to corticosteroid treatment. In addition, the benefit of corticosteroid treatment may be outweighed by the side effects. Long-term administration of inhaled steroids is a safe means of treatment. We hypothesized that treatment with high-dose inhaled budesonide would improve clinical symptoms and pulmonary function in subjects with COPD, and that the response to inhaled β2-agonist will serve to individualize steroid responders. We compared a 6-week course of 800 µg/d inhaled budesonide with placebo, separated by 4 weeks when no medication was taken, in a double-blind crossover trial, in 8 patients responding to inhaled β2-agonist, and in 22 nonresponders with stable COPD. Full-Text PDF Inhaled Corticosteroids in COPD: A Light at the End of the Tunnel?CHESTVol. 108Issue 6PreviewCOPD is characterized by a progressive deterioration of lung function with an FEV1 decline averaging 70 mL/yr. In bronchial asthma, the rate of decrement is only 5 mL/yr.1 This low decline in FEV1 has been attributed to the widespread use of corticosteroids and bronchodilators,2,3 which suppress inflammation and decrease airway hyperresponsiveness. In COPD, FEV1 decline is sustained and only cessation of smoking decreases the progression of lung function deterioration.4,5 Full-Text PDF" @default.
• W1973106424 created "2016-06-24" @default.
• W1973106424 creator A5088228966 @default.
• W1973106424 date "1996-06-01" @default.
• W1973106424 modified "2023-09-26" @default.
• W1973106424 title "Who Benefits From Inhaled Corticosteroids?" @default.
• W1973106424 cites W1965778252 @default.
• W1973106424 cites W2008538178 @default.
• W1973106424 cites W2073615621 @default.
• W1973106424 cites W2083681919 @default.
• W1973106424 doi "https://doi.org/10.1378/chest.109.6.1666" @default.
• W1973106424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8769537" @default.
• W1973106424 hasPublicationYear "1996" @default.
• W1973106424 type Work @default.
• W1973106424 sameAs 1973106424 @default.
• W1973106424 citedByCount "0" @default.
• W1973106424 crossrefType "journal-article" @default.
• W1973106424 hasAuthorship W1973106424A5088228966 @default.
• W1973106424 hasBestOaLocation W19731064241 @default.
• W1973106424 hasConcept C126322002 @default.
• W1973106424 hasConcept C142724271 @default.
• W1973106424 hasConcept C170493617 @default.
• W1973106424 hasConcept C204787440 @default.
• W1973106424 hasConcept C27081682 @default.
• W1973106424 hasConcept C2776042228 @default.
• W1973106424 hasConcept C2776136866 @default.
• W1973106424 hasConcept C2776715498 @default.
• W1973106424 hasConcept C2776780178 @default.
• W1973106424 hasConcept C2776804153 @default.
• W1973106424 hasConcept C2778938600 @default.
• W1973106424 hasConcept C2991922776 @default.
• W1973106424 hasConcept C71924100 @default.
• W1973106424 hasConceptScore W1973106424C126322002 @default.
• W1973106424 hasConceptScore W1973106424C142724271 @default.
• W1973106424 hasConceptScore W1973106424C170493617 @default.
• W1973106424 hasConceptScore W1973106424C204787440 @default.
• W1973106424 hasConceptScore W1973106424C27081682 @default.
• W1973106424 hasConceptScore W1973106424C2776042228 @default.
• W1973106424 hasConceptScore W1973106424C2776136866 @default.
• W1973106424 hasConceptScore W1973106424C2776715498 @default.
• W1973106424 hasConceptScore W1973106424C2776780178 @default.
• W1973106424 hasConceptScore W1973106424C2776804153 @default.
• W1973106424 hasConceptScore W1973106424C2778938600 @default.
• W1973106424 hasConceptScore W1973106424C2991922776 @default.
• W1973106424 hasConceptScore W1973106424C71924100 @default.
• W1973106424 hasIssue "6" @default.
• W1973106424 hasLocation W19731064241 @default.
• W1973106424 hasLocation W19731064242 @default.
• W1973106424 hasOpenAccess W1973106424 @default.
• W1973106424 hasPrimaryLocation W19731064241 @default.
• W1973106424 hasRelatedWork W1862318975 @default.
• W1973106424 hasRelatedWork W1988458034 @default.
• W1973106424 hasRelatedWork W2018965898 @default.
• W1973106424 hasRelatedWork W2057973646 @default.
• W1973106424 hasRelatedWork W2122246164 @default.
• W1973106424 hasRelatedWork W2390425158 @default.
• W1973106424 hasRelatedWork W2404861763 @default.
• W1973106424 hasRelatedWork W2438744654 @default.
• W1973106424 hasRelatedWork W2440163331 @default.
• W1973106424 hasRelatedWork W3026608136 @default.
• W1973106424 hasVolume "109" @default.
• W1973106424 isParatext "false" @default.
• W1973106424 isRetracted "false" @default.
• W1973106424 magId "1973106424" @default.
• W1973106424 workType "article" @default.